Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (QLGN) Stock Ownership
Latest 13F position summary is not yet available — breakdown and tables fill in after filings publish (typically ~45 days after quarter end).
SEC 13F · FMP · QLGN · as of —
Ownership Breakdown
Institutional data for this period is not yet available. SEC Form 13F filings are typically published 45 days after quarter end.
No institutional data available for this period.
Insider Buying vs Selling
QLGN insider trading · insider activity
Source: SEC Form 4
11
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Abdul-Ahad Wajdi Vice President, R & D, CSO | Jul 11, 2022 | Award | 80,000 | — | — | 80.0K | Form 4 ↗ |
Lotz Christopher L. Vice President of Finance, CFO | Jul 11, 2022 | Award | 100,000 | $0.51 | $51.4K | 100.0K | Form 4 ↗ |
Lotz Christopher L. Vice President of Finance, CFO | Jul 11, 2022 | Award | 100,000 | — | — | 100.0K | Form 4 ↗ |
ARSHAD TARIQ SVP/Chief Medical Officer | Jul 11, 2022 | Award | 102,000 | — | — | 102.0K | Form 4 ↗ |
Ritter Ira E. director | Jul 11, 2022 | Award | 40,000 | $0.51 | $20.5K | 40.0K | Form 4 ↗ |
Ritter Ira E.
| Jul 11, 2022 | Award | 40,000 | — | — | 40.0K | Form 4 ↗ |
EMERY SIDNEY W JR director | Jul 11, 2022 | Award | 40,000 | $0.51 | $20.5K | 40.0K | Form 4 ↗ |
EMERY SIDNEY W JR
| Jul 11, 2022 | Award | 40,000 | — | — | 40.0K | Form 4 ↗ |
Kruger Kurt H
| Jul 11, 2022 | Award | 40,000 | — | — | 40.0K | Form 4 ↗ |
David Richard A. director | Jul 11, 2022 | Award | 40,000 | $0.51 | $20.5K | 40.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Qualigen Therapeutics, Inc. (QLGN) is primarily owned by institutional investors, who hold approximately — of total shares outstanding. Company insiders own approximately —, while retail and public investors account for the remaining —.
A total of 0 institutional investors currently hold QLGN stock, with a combined institutional value of approximately $0 as of the most recent 13F filing period.
Frequently asked questions
QLGN ownershipQualigen Therapeutics, Inc. (QLGN) is primarily owned by institutional investors, who hold approximately — of shares. The largest shareholder is — with a — stake. Company insiders hold —. Data sourced from SEC Form 13F as of —.